News & Media
Main Menu
Presentations
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates. ECE 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients. ECE 2023 Poster.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients. ECE 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Treatment of Chronic Hypoparathyroidism by Eneboparatide, a Novel PTH Receptor-1 Agonist: Results from a Phase 2a Study. ECE 2023 Presentation.
Written by
Dan Hennings
Upcoming events
39th Congress of the French Society of Endocrinology
Date: October 4-7, 2023 (Marseilles, France)
BIO Japan 2023
Date: October 11-13, 2023 (Yokohama, Japan)
American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR)
Date: October 13-16, 2023 (Vancouver, Canada)
Acromegaly Awareness Day
Date: November 1, 2023
2023 International HypoPARAthyroidism Conference
Date: November 3-4, 2023 (Sterling, VA)
Social Updates
TWITTER